Share on StockTwits
 

Equities research analysts at Stifel Nicolaus hoisted their price target on shares of NewLink Genetics Corp. (NASDAQ:NLNK) from $31.00 to $53.00 in a research note issued to investors on Wednesday, AR Network reports. The firm currently has a “buy” rating on the stock. Stifel Nicolaus’ target price would indicate a potential upside of 51.34% from the stock’s previous close. The analysts noted that the move was a valuation call.

Shares of NewLink Genetics Corp. (NASDAQ:NLNK) traded up 0.43% on Wednesday, hitting $35.17. The stock had a trading volume of 405,360 shares. NewLink Genetics Corp. has a 1-year low of $11.19 and a 1-year high of $35.26. The stock has a 50-day moving average of $23.67 and a 200-day moving average of $19.4. The company’s market cap is $904.1 million.

NewLink Genetics Corp. (NASDAQ:NLNK) last released its earnings data on Monday, November 11th. The company reported ($0.32) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.33) by $0.01. During the same quarter in the prior year, the company posted ($0.28) earnings per share. On average, analysts predict that NewLink Genetics Corp. will post $-1.29 earnings per share for the current fiscal year.

NewLink Genetics Corporation operates as a biopharmaceutical company. The Company, based in the United States, is focused on discovering, developing, and commercializing immunotherapeutic products to improve cancer treatment options for patients and physicians.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.